|
2025-10-03 |
2025-10-02 |
S
Venta
|
EVP Operations
Oficial
|
76 121
+19.4%
287,48
2.606.307 US$
|
76 121
+19.4%
|
287,48
|
2.606.307 US$
|
|
|
2025-08-26 |
2025-08-22 |
S
Venta
|
EVP Operations
Oficial
|
60 063
-39.2%
304,58
4.075.820 US$
|
60 063
-39.2%
|
304,58
|
4.075.820 US$
|
|
|
2025-08-22 |
2025-08-22 |
PrS
Venta propuesta
|
Officer
Oficial
|
74 884
52,22
4.500.875 US$
|
74 884
|
52,22
|
4.500.875 US$
|
|
|
2025-07-25 |
2025-07-10 |
B
Compra
|
Chief Commercial Officer
Oficial
|
16 366
+inf%
0,59
9.640 US$
|
16 366
+inf%
|
0,59
|
9.640 US$
|
|
|
2025-07-10 |
2025-07-08 |
S
Venta
|
EVP Operations
Oficial
|
200 000
-8.0%
0,58
115.800 US$
|
200 000
-8.0%
|
0,58
|
115.800 US$
|
|
|
2025-07-08 |
2025-07-08 |
PrS
Venta propuesta
|
Officer
Oficial
|
500 000
0,61
303.000 US$
|
500 000
|
0,61
|
303.000 US$
|
|
|
2024-10-28 |
2024-10-24 |
S
Venta
|
SVP of Operations
Oficial
|
333 932
-100.0%
0,51
170.305 US$
|
333 932
-100.0%
|
0,51
|
170.305 US$
|
|
|
2024-10-28 |
2024-10-23 |
S
Venta
|
SVP of Operations
Oficial
|
800 000
-70.6%
0,49
392.000 US$
|
800 000
-70.6%
|
0,49
|
392.000 US$
|
|
|
2024-10-23 |
2024-10-23 |
PrS
Venta propuesta
|
Officer
Oficial
|
1 133 932
0,60
680.359 US$
|
1 133 932
|
0,60
|
680.359 US$
|
|
|
2016-03-21 |
2016-03-18 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
258 090
-3.3%
0,34
88.267 US$
|
258 090
-3.3%
|
0,34
|
88.267 US$
|
|
|
2016-03-21 |
2016-03-17 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
312 430
-3.8%
0,35
107.788 US$
|
312 430
-3.8%
|
0,35
|
107.788 US$
|
|
|
2016-02-24 |
2016-02-24 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
100 456
-1.2%
0,31
31.141 US$
|
100 456
-1.2%
|
0,31
|
31.141 US$
|
|
|
2016-02-24 |
2016-02-22 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
100 000
-1.2%
0,32
32.090 US$
|
100 000
-1.2%
|
0,32
|
32.090 US$
|
|
|
2016-02-18 |
2016-02-17 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
50 000
-0.6%
0,31
15.580 US$
|
50 000
-0.6%
|
0,31
|
15.580 US$
|
|
|
2016-02-18 |
2016-02-05 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
24 400
-0.3%
0,33
8.052 US$
|
24 400
-0.3%
|
0,33
|
8.052 US$
|
|
|
2016-02-18 |
2016-02-04 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
349 660
-4.0%
0,32
111.891 US$
|
349 660
-4.0%
|
0,32
|
111.891 US$
|
|
|
2016-02-18 |
2016-02-03 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
45 518
-0.5%
0,33
15.021 US$
|
45 518
-0.5%
|
0,33
|
15.021 US$
|
|
|
2016-02-18 |
2016-02-02 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
13 000
-0.1%
0,33
4.290 US$
|
13 000
-0.1%
|
0,33
|
4.290 US$
|
|
|
2016-02-18 |
2016-02-01 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
312 300
-3.4%
0,34
106.182 US$
|
312 300
-3.4%
|
0,34
|
106.182 US$
|
|
|
2016-02-18 |
2016-01-29 |
S
Venta
|
TREPPEL JERRY
former Chairman
|
115 000
-1.3%
0,35
40.250 US$
|
115 000
-1.3%
|
0,35
|
40.250 US$
|
|
|
2015-11-18 |
2015-11-18 |
S
Venta
|
TREPPEL JERRY
Chairman of Board
Consejero ejecutivo
|
25 000
-0.3%
0,31
7.625 US$
|
25 000
-0.3%
|
0,31
|
7.625 US$
|
|
|
2015-11-18 |
2015-11-17 |
S
Venta
|
TREPPEL JERRY
Chairman of Board
Consejero ejecutivo
|
25 000
-0.3%
0,30
7.502 US$
|
25 000
-0.3%
|
0,30
|
7.502 US$
|
|
|
2015-11-18 |
2015-11-16 |
S
Venta
|
TREPPEL JERRY
Chairman of Board
Consejero ejecutivo
|
50 000
-0.5%
0,30
15.125 US$
|
50 000
-0.5%
|
0,30
|
15.125 US$
|
|
|
2015-11-18 |
2015-11-13 |
S
Venta
|
TREPPEL JERRY
Chairman of Board
Consejero ejecutivo
|
50 000
-0.5%
0,30
15.000 US$
|
50 000
-0.5%
|
0,30
|
15.000 US$
|
|
|
2015-04-28 |
2015-04-27 |
S
Venta
|
Plassche Douglas
Executive VP of Operations
Oficial
|
85 530
-53.9%
0,24
20.168 US$
|
85 530
-53.9%
|
0,24
|
20.168 US$
|
|
|
2014-09-29 |
2014-09-26 |
B
Compra
|
Hakim Nasrat A
CEO & President
Consejero ejecutivo
|
265 500
+10.9%
0,31
82.385 US$
|
265 500
+10.9%
|
0,31
|
82.385 US$
|
|
|
2014-09-29 |
2014-09-25 |
B
Compra
|
Hakim Nasrat A
CEO & President
Consejero ejecutivo
|
434 500
+21.7%
0,31
133.956 US$
|
434 500
+21.7%
|
0,31
|
133.956 US$
|
|
|
2014-05-13 |
2014-05-09 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
329 437
-5.6%
0,38
125.944 US$
|
329 437
-5.6%
|
0,38
|
125.944 US$
|
|
|
2014-04-04 |
2014-04-02 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
147 664
-2.5%
0,41
60.542 US$
|
147 664
-2.5%
|
0,41
|
60.542 US$
|
|
|
2014-03-31 |
2014-03-27 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
190 172
-3.1%
0,43
81.165 US$
|
190 172
-3.1%
|
0,43
|
81.165 US$
|
|
|
2014-03-17 |
2014-03-11 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
239 367
-1.2%
0,60
144.003 US$
|
239 367
-1.2%
|
0,60
|
144.003 US$
|
|
|
2014-03-17 |
2014-03-11 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
239 367
-0.4%
0,60
144.003 US$
|
239 367
-0.4%
|
0,60
|
144.003 US$
|
|
|
2014-03-17 |
2014-03-11 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
239 367
-1.6%
0,60
144.003 US$
|
239 367
-1.6%
|
0,60
|
144.003 US$
|
|
|
2014-03-17 |
2014-03-11 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
239 367
-0.4%
0,60
144.003 US$
|
239 367
-0.4%
|
0,60
|
144.003 US$
|
|
|
2014-03-10 |
2014-03-07 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
1 051 450
-6.6%
0,68
714.986 US$
|
1 051 450
-6.6%
|
0,68
|
714.986 US$
|
|
|
2014-03-10 |
2014-03-07 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
1 051 450
-4.9%
0,68
714.986 US$
|
1 051 450
-4.9%
|
0,68
|
714.986 US$
|
|
|
2014-03-10 |
2014-03-07 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
1 051 450
-1.5%
0,68
714.986 US$
|
1 051 450
-1.5%
|
0,68
|
714.986 US$
|
|
|
2014-03-10 |
2014-03-07 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
1 051 450
-1.5%
0,68
714.986 US$
|
1 051 450
-1.5%
|
0,68
|
714.986 US$
|
|
|
2014-03-10 |
2014-03-06 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
773 050
-4.8%
0,90
692.344 US$
|
773 050
-4.8%
|
0,90
|
692.344 US$
|
|
|
2014-03-10 |
2014-03-06 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
773 050
-3.6%
0,90
692.344 US$
|
773 050
-3.6%
|
0,90
|
692.344 US$
|
|
|
2014-03-10 |
2014-03-06 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
773 050
-1.1%
0,90
692.344 US$
|
773 050
-1.1%
|
0,90
|
692.344 US$
|
|
|
2014-03-10 |
2014-03-06 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
773 050
-1.1%
0,90
692.344 US$
|
773 050
-1.1%
|
0,90
|
692.344 US$
|
|
|
2014-01-17 |
2014-01-13 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
805 583
-1.1%
0,18
147.422 US$
|
805 583
-1.1%
|
0,18
|
147.422 US$
|
|
|
2014-01-17 |
2014-01-13 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
805 583
-5.0%
0,18
147.422 US$
|
805 583
-5.0%
|
0,18
|
147.422 US$
|
|
|
2014-01-17 |
2014-01-13 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
805 583
-3.7%
0,18
147.422 US$
|
805 583
-3.7%
|
0,18
|
147.422 US$
|
|
|
2014-01-17 |
2014-01-13 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
805 538
-1.1%
0,18
147.413 US$
|
805 538
-1.1%
|
0,18
|
147.413 US$
|
|
|
2013-12-16 |
2013-12-05 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
275 000
-0.4%
0,13
34.512 US$
|
275 000
-0.4%
|
0,13
|
34.512 US$
|
|
|
2013-12-13 |
2013-12-05 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
275 000
-0.4%
0,13
34.512 US$
|
275 000
-0.4%
|
0,13
|
34.512 US$
|
|
|
2013-12-13 |
2013-12-05 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
275 000
-1.7%
0,13
34.512 US$
|
275 000
-1.7%
|
0,13
|
34.512 US$
|
|
|
2013-12-13 |
2013-12-05 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
275 000
-1.3%
0,13
34.512 US$
|
275 000
-1.3%
|
0,13
|
34.512 US$
|
|
|
2013-12-04 |
2013-12-02 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
100 000
-0.1%
0,13
12.520 US$
|
100 000
-0.1%
|
0,13
|
12.520 US$
|
|
|
2013-12-04 |
2013-12-02 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
100 000
-0.1%
0,13
12.520 US$
|
100 000
-0.1%
|
0,13
|
12.520 US$
|
|
|
2013-12-04 |
2013-12-02 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
100 000
-0.5%
0,13
12.520 US$
|
100 000
-0.5%
|
0,13
|
12.520 US$
|
|
|
2013-11-29 |
2013-11-27 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
25 000
-0.0%
0,12
3.030 US$
|
25 000
-0.0%
|
0,12
|
3.030 US$
|
|
|
2013-11-29 |
2013-11-27 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
25 000
-0.1%
0,12
3.030 US$
|
25 000
-0.1%
|
0,12
|
3.030 US$
|
|
|
2013-11-29 |
2013-11-27 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
25 000
-0.2%
0,12
3.030 US$
|
25 000
-0.2%
|
0,12
|
3.030 US$
|
|
|
2013-11-29 |
2013-11-27 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
25 000
-0.0%
0,12
3.030 US$
|
25 000
-0.0%
|
0,12
|
3.030 US$
|
|
|
2013-12-16 |
2013-11-26 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
23 626
-0.0%
0,12
2.793 US$
|
23 626
-0.0%
|
0,12
|
2.793 US$
|
|
|
2013-12-13 |
2013-11-26 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
23 626
-0.0%
0,12
2.793 US$
|
23 626
-0.0%
|
0,12
|
2.793 US$
|
|
|
2013-12-13 |
2013-11-26 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
23 626
-0.2%
0,12
2.793 US$
|
23 626
-0.2%
|
0,12
|
2.793 US$
|
|
|
2013-12-13 |
2013-11-26 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
23 626
-0.1%
0,12
2.793 US$
|
23 626
-0.1%
|
0,12
|
2.793 US$
|
|
|
2013-11-29 |
2013-11-26 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
357 000
-0.5%
0,12
43.126 US$
|
357 000
-0.5%
|
0,12
|
43.126 US$
|
|
|
2013-11-29 |
2013-11-26 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
357 000
-1.6%
0,12
43.126 US$
|
357 000
-1.6%
|
0,12
|
43.126 US$
|
|
|
2013-11-29 |
2013-11-26 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
357 000
-2.2%
0,12
43.126 US$
|
357 000
-2.2%
|
0,12
|
43.126 US$
|
|
|
2013-11-29 |
2013-11-26 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
357 000
-0.5%
0,12
43.126 US$
|
357 000
-0.5%
|
0,12
|
43.126 US$
|
|
|
2013-11-19 |
2013-11-19 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
21 000
-0.0%
0,12
2.457 US$
|
21 000
-0.0%
|
0,12
|
2.457 US$
|
|
|
2013-11-19 |
2013-11-19 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
21 000
-0.1%
0,12
2.499 US$
|
21 000
-0.1%
|
0,12
|
2.499 US$
|
|
|
2013-11-19 |
2013-11-19 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
21 000
-0.1%
0,12
2.457 US$
|
21 000
-0.1%
|
0,12
|
2.457 US$
|
|
|
2013-11-19 |
2013-11-19 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
21 000
-0.0%
0,12
2.457 US$
|
21 000
-0.0%
|
0,12
|
2.457 US$
|
|
|
2013-11-19 |
2013-11-18 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
1 170 000
-1.6%
0,12
137.475 US$
|
1 170 000
-1.6%
|
0,12
|
137.475 US$
|
|
|
2013-11-19 |
2013-11-18 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
1 170 000
-6.9%
0,12
137.475 US$
|
1 170 000
-6.9%
|
0,12
|
137.475 US$
|
|
|
2013-11-19 |
2013-11-18 |
S
Venta
|
NIGALAYE ASHOK G
Chief Scientific Officer
Consejero ejecutivo
Gran accionista
|
1 170 000
-5.1%
0,12
137.475 US$
|
1 170 000
-5.1%
|
0,12
|
137.475 US$
|
|
|
2013-11-19 |
2013-11-18 |
S
Venta
|
EPIC PHARMA LLC
Gran accionista
|
1 170 000
-1.6%
0,12
137.475 US$
|
1 170 000
-1.6%
|
0,12
|
137.475 US$
|
|
|
2013-11-19 |
2013-11-15 |
S
Venta
|
EPIC INVESTMENTS, LLC
Gran accionista
|
318 050
-0.4%
0,12
37.307 US$
|
318 050
-0.4%
|
0,12
|
37.307 US$
|
|
|
2013-11-19 |
2013-11-15 |
S
Venta
|
NARINE JEENARINE
Consejero no ejecutivo
Gran accionista
|
318 050
-1.9%
0,12
37.307 US$
|
318 050
-1.9%
|
0,12
|
37.307 US$
|
|